Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer

被引:1
作者
Kadkhodayan, Sima [1 ]
Shandiz, Fatemeh Homaei [2 ]
Toussi, Mehdi Seilanian [2 ]
Aghaee, Monavar Afzal [3 ]
Farshidi, Farnoosh [4 ]
Dehghan, Parvane [5 ]
机构
[1] Mashhad Univ Med Sci, Ghaem Hosp, Womens Hlth Res Ctr, Mashhad, Iran
[2] Mashhad Univ Med Sci, Ghaem Hosp, Solid Tumor Treatment Res Ctr, Mashhad, Iran
[3] Mashhad Univ Med Sci, Dept Epidemiol, Mashhad, Iran
[4] Mashhad Univ Med Sci, Ghaem Hosp, Mashhad, Iran
[5] Mashhad Univ Med Sci, Dept Radiat Oncol, Mashhad, Iran
关键词
Cervical cancer; Radiotherapy; Concurrent chemoradiotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy. Methods: In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated. Results: 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2year overall survival rate of 58.7% +/- 9% and 2-year disease free survival of 37.7% +/- 9%. Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded. Conclusion: Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 26 条
[1]   External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed [J].
Barraclough, Lisa Helen ;
Swindell, Ric ;
Livsey, Jacqueline E. ;
Hunter, Robin D. ;
Davidson, Susan E. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03) :772-778
[2]   Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study [J].
Chan, Philip ;
Yeo, Inhwan ;
Perkins, Gregory ;
Fyles, Anthony ;
Milosevic, Michael .
RADIATION ONCOLOGY, 2006, 1 (1)
[3]   Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01 [J].
Eifel, PJ ;
Winter, K ;
Morris, M ;
Levenback, C ;
Grigsby, PW ;
Cooper, J ;
Rotman, M ;
Gershenson, D ;
Mutch, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :872-880
[4]  
Eifel PJ, 2011, CANC PRINCIPLES PRAC, P1311
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[7]   A Dosimetric Planning Study Comparing Intensity-modulated Radiotherapy with Four-field Conformal Pelvic Radiotherapy for the Definitive Treatment of Cervical Carcinoma [J].
Forrest, J. ;
Presutti, J. ;
Davidson, M. ;
Hamilton, P. ;
Kiss, A. ;
Thomas, G. .
CLINICAL ONCOLOGY, 2012, 24 (04) :E63-E70
[8]   Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix - art. no. CD00225.pub2 [J].
Green, J ;
Kirwan, J ;
Tierney, J ;
Vale, C ;
Symonds, P ;
Fresco, L ;
Williams, C ;
Collingwood, M .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03)
[9]   Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis [J].
Green, JA ;
Kirwan, JM ;
Tierney, JF ;
Symonds, P ;
Fresco, L ;
Collingwood, M ;
Williams, CJ .
LANCET, 2001, 358 (9284) :781-786
[10]   CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy [J].
Haas, Jonathan Andrew ;
Witten, Matthew R. ;
Clancey, Owen ;
Episcopia, Karen ;
Accordino, Diane ;
Chalas, Eva .
FRONTIERS IN ONCOLOGY, 2012, 2